Palliative care for people with blood cancers receiving cell therapy
Tests extra palliative care support in adults with lymphoma, leukemia or myeloma receiving cell therapy.
Plain-language title generated from the registry record
Registry title: Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
Key facts
- Where
- Boston, United StatesSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a blood cancer who are getting their own cells as an approved cellular therapy at MGH. It tests adding palliative care to usual cancer care.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- A blood cancer (hematologic malignancy), such as lymphoma, leukemia or multiple myeloma
- Earlier treatment
- Receiving autologous adoptive cellular therapy (ACT) at MGH with an FDA approved cellular therapy product. Cannot already be receiving palliative care.
Main reasons for not taking part
- Impaired thinking or uncontrolled mental illness that stops them from taking part in the study
- Already receiving palliative care
Read by machine on 9 November 2026.
Where in United States
- Massachusetts General Hospital Cancer CenterBoston, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Massachusetts General Hospital
- Trial code
- NCT05646576
- Record updated
- 21 April 2026
- Original description
The goal of this study is to determine whether a palliative care intervention (PEACE) can improve the quality of life and experiences of participants with Lymphoma, Leukemia, or Multiple Myeloma receiving adoptive cellular therapy (ACT). After completion of an open pilot, participants will be randomly assigned into one of two study intervention groups.Read full original descriptionShow less
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy: The PEACE Study
The goal of this study is to determine whether a palliative care intervention (PEACE) can improve the quality of life and experiences of participants with Lymphoma, Leukemia, or Multiple Myeloma receiving adoptive cellular therapy (ACT). After completion of an open pilot, participants will be randomly assigned into one of two study intervention groups.
The names of the study intervention groups involved in this study are:
* Palliative care (PEACE) plus usual oncology care * Usual care (standard oncology care)
Participation in this research study is expected to last for up to 2 years.
It is expected that about 90 people will take part in this research study.
Inclusion: Age 18 years or older; Ability to complete surveys in English or with assistance of an interpreter; Diagnosis of a hematologic malignancy; Receiving autologous adoptive cellular therapy (ACT) at MGH with an FDA approved cellular therapy product.
Exclusion: Already receiving palliative care (PC); Impaired cognition or uncontrolled mental illness that prohibits study compliance based on the oncology clinician assessment.